...
首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >The Antitumour Effect of Prunella vulgaris Extract on Thyroid Cancer Cells In Vitro and In Vivo
【24h】

The Antitumour Effect of Prunella vulgaris Extract on Thyroid Cancer Cells In Vitro and In Vivo

机译:Prunella Vulgaris提取物在体外和体内甲状腺癌细胞上的抗肿瘤作用

获取原文
           

摘要

Prunella vulgaris , a traditional Chinese medicine, has been used to treat various benign and malignant tumours for centuries in China. In our previous studies, Prunella vulgaris extract (PVE) was shown to promote apoptosis in differentiated thyroid cancer (DTC) cells. However, whether other mechanisms are involved in the antitumour effect of PVE in thyroid cancer (TC) cells remains unclear. The present study aimed to investigate the antiproliferative and antimigratory effects of PVE on TC cell lines both in vitro and in vivo. First, the TPC-1 and SW579 human TC cell lines were screened by MTT assay for their high level of sensitivity to PVE. Then, the results of cell growth curve and colony formation assay and cell cycle analyses, wound healing, and migration assays demonstrated that PVE inhibited the proliferation and migration of TPC-1 and SW579 cells. Moreover, the antitumour effect of PVE was verified in a subcutaneous xenotransplanted tumour model. Next, MKI67, PCNA, CTNNB1, and CDH1 were screened by qRT-PCR for their significantly differential expression levels in xenograft tissue with and without PVE treatment, and expression of MKI67, PCNA, and CDH1 was verified by Western blot. Finally, an integrated bioinformatics analysis containing protein-protein interaction network, KEGG pathway, and GO analysis was conducted to explore more potential antitumour mechanisms of PVE. In summary, PVE could inhibit the proliferation and migration of TC cells both in vitro and in vivo, which may have been achieved by modulation of the expression of MKI67, PCNA, and CDH1. These data suggest that PVE has the potential to be developed into a new anticancer drug for the treatment of TC.
机译:普鲁尼亚寻常蛋白是一种中医,已被用于治疗中国几个世纪的良性和恶性肿瘤。在我们以前的研究中,Prunella寻常提取物(PVE)显示出促进分化的甲状腺癌(DTC)细胞中的凋亡。然而,其他机制是否参与甲状腺癌(TC)细胞中PVE的抗肿瘤效果仍然不清楚。本研究旨在探讨PVE对体外和体内TC细胞系PVE的抗增殖和抗牵引作用。首先,通过MTT测定筛选TPC-1和SW579人TC细胞系,以使其对PVE的高敏感性。然后,细胞生长曲线和菌落形成测定的结果和细胞周期分析,伤口愈合和迁移测定表明,PVE抑制了TPC-1和SW579细胞的增殖和迁移。此外,在皮下异种翻透肿瘤模型中验证了PVE的抗肿瘤效应。接下来,通过QRT-PCR筛选MKI67,PCNA,CTNNB1和CDH1,用于卵黄移植组织中具有显着差异的表达水平,无需PVE处理,并通过Western印迹验证MKI67,PCNA和CDH1的表达。最后,进行了含有蛋白质 - 蛋白质相互作用网络,Kegg途径和去分析的集成生物信息分析,以探讨PVE的更多潜在的抗胃抑制机制。总之,PVE可以通过调制MKI67,PCNA和CDH1的表达,抑制体外和体内TC细胞的增殖和迁移。这些数据表明,PVE有可能开发成用于治疗TC的新抗癌药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号